Background: Paraoxonase 1 (PON1) is a calcium-dependent esterase and exerts antioxidant and antiatherogenic properties. Advanced oxidation protein products (AOPP) are a group of carbonylated protein products showing oxidant-mediated protein damage. This study aimed to deter-mine serum PON1 activities and AOPP concentrations in diabetic patients and to evaluate these parameters in terms of their relationships with diabetes mellitus (DM) and related factors. Methods: A total of 93 patients diagnosed with type 2 DM and 30 healthy controls were enrolled in the study. Serum AOPP levels and PON1 activities were measured spectrophotometrically. Other biochemical parameters, includ-ing glucose, total cholesterol, HDL-C, LDL-C, triglycerides, HbA1c and clinical/demographic data, were measured in the routine blood chemistry laboratory and retrieved from patient files. Results: Serum PON1 activity was significantly lower in patients with DM (31.6 2 1.4 9-48.45 U/mL) compared to controls (41.08 2 9.0 7-54.35 U/mL) (p= 0.028). Serum AOPP concentration was significantly higher in diabetic patients (584.6 4 53.8-778.6 pmol/L) than in controls (173.9 9 8.7 7-224.1 pmol/L) (p 340 mmol/L predicted DM with a sensitivity of 89.25% and specificity of 93.33% (AUC: 0.965). Both PON1 (OR: 10.82 1, 95% CI: 1.959 59.778, p= 0.006) and AOPP (OR: 190.068, 95% CI: 20.1 0 2-1 7 9 7.1 4 8, p< 0.001) were independently associated with DM after adjusting for age, sex, and weight. Conclusions: AOPP and PON1 may play a significant role in the development and progression of DM. In particular, serum AOPP concentrations appear to be distinctive among patients with new-onset DM.
KOLDAŞ et al. (Thu,) studied this question.